Nolla Health Launches AI-Issued Initial Acne Prescriptions in Utah

Nolla Health announced on October 5, 2026, that its Nolla Derm app is issuing AI-generated initial acne prescriptions to Utah residents 18 and older under a state regulatory agreement, at a pilot price of $4.99 per month. The company said it is the first organization in the United States authorized by a state regulator for AI to issue an initial prescription rather than a refill.

Utah residents can download the app, opt into the pilot, verify their identity, complete an informed-consent flow and a short intake questionnaire, and take a five-angle face scan. According to the company, the process takes about 10 to 15 minutes and yields a personalized treatment plan and, if appropriate, an initial prescription, with no existing prescription required. Co-founder and CEO Luis Wenus said the service is intended to deliver acne care with no office visit and no unaffordable bill. The company’s Nolla Derm product page describes the pilot as live for Utah adults.

The State Regulatory Agreement

The pilot operates under an agreement between the Office of Artificial Intelligence Policy, the Division of Professional Licensing, and Nolla Health’s operating entities, Magic Health, Inc. and its subsidiary Magic Health Services, LLC. Both state bodies sit within the Utah Department of Commerce. The state’s public record of authorized AI pilots lists the Nolla pilot as approved and signed September 22, 2026, and the signed agreement carries company executive signatures dated September 21, 2026.

Under the agreement, the division agreed not to bring an enforcement action for unlicensed or unprofessional conduct, or under the state’s telehealth requirements, where Nolla’s AI issues first-time topical acne prescriptions or renewals to eligible Utah adults and transmits them to a Utah-licensed pharmacist. The same protection covers physicians working with Nolla Health who rely on the system for that purpose, and it reaches only the provisions named in the agreement’s Schedule A. The agreement runs 12 months from its commencement date, defined as the date Nolla makes the technology available to customers and notifies the office in writing, and it states that it is a grant of regulatory mitigation only, not an endorsement or approval by the State of Utah.

Sandbox agreements are limited by statute to 12-month demonstration periods with at most two 12-month extensions, and the office may end one at any time. Every participant reports monthly with quantitative metrics, the office audits participants while agreements are in force, and it reports to the Legislature’s Business and Labor Interim Committee before November 30 each year. The office said it has also finalized agreements with independent third-party evaluators to audit healthcare AI sandbox pilots by stress-testing system guardrails, inspecting decision logs, and evaluating patient outcomes. Nolla’s announcement said residents could enroll beginning October 5, 2026, and its product page describes the pilot as live; the state’s public pilot record listed the demonstration period as not yet started.

Prescribing Scope, Hard Stops, and Patient Flow

The authorization is narrow. The AI may issue first-time prescriptions and renewals for topical acne treatment only, to Utah adults with mild to moderate acne, from a set list of creams and gels; oral medication, isotretinoin, and severe acne are outside the pilot. The formulary written into the agreement covers tretinoin, adapalene, clindamycin with benzoyl peroxide, benzoyl peroxide, and azelaic acid, plus compounded versions formulated with niacinamide and, in two formulations, topical spironolactone. The AI may not initiate or recommend any therapy beyond that list.

Intake screens for hard-stop conditions that route a patient to a physician or out of the pilot. Acne scoring above 3.5 on the five-point Investigator Global Assessment severity scale is escalated for physician review before any prescription, and a score of 4.0 directs the patient to in-person dermatological care. Pregnancy, plans to become pregnant, breastfeeding, immunosuppression, severe kidney or liver disease, a prior reaction to a formulary medication, being under 18, failed identity verification, or a non-Utah address each stop the process. Severity is scored by the AI from the face-scan images rather than by patient self-report.

Identity and age are verified through Stripe Identity using a government-issued photo ID and a selfie, and residency is confirmed through phone geolocation and the delivery address; prescriptions go only to Utah addresses. Every prescription is transmitted under the overseeing physician’s NPI and identified in the record as AI-initiated, and each pharmacy receiving one is informed that AI generated it and given contact information for Nolla’s physicians. During the pilot the app costs $4.99 per month, discounted from the standard $9.99, and patients choose home-delivered compounded medication at $49.99, covering morning and evening treatments, or generic equivalents that typically cost $10 to $40 at a local pharmacy. Nolla’s proposal states that the compounded price is a pass-through to its compounding partner and that it receives no referral fees. Treatment plans are reviewed after every 28 daily scans, and patients can message a licensed physician at no extra cost; the company said a physician, rather than the AI, answers those messages.

Stage-Gated Oversight and Reported Validation

Physician oversight steps down through three stages. Stage one runs a minimum of four weeks and covers the first 100 patients, during which every AI-generated prescription must be reviewed and approved independently by two Utah-licensed physicians before reaching the patient. In stage two, at least eight weeks and up to 500 cumulative patients, the AI issues prescriptions directly while physicians review every case retrospectively at least weekly. From stage three, at 750 cumulative patients, physicians review a monthly sample of at least 10% of volume plus every case involving an adverse event or escalation. Advancing requires written approval from the office and targets of at least 95% agreement between the AI and reviewing physicians, zero missed hard stops after sampling-based human review, and zero serious adverse events; any serious adverse event triggers an immediate review and pause.

The agreement requires Nolla to report adverse events to the office within 24 hours across enumerated categories and to file monthly reports by the 15th of the following month covering case counts, prescriptions by drug, clinician agreement rates, escalation reasons, and patient demographics. Quarterly reports are made public by the office, and de-identified individual-level data goes to office-vetted third-party auditors for external validation.

In its proposal to the state, Nolla reported that its severity-scoring model was trained on more than 100,000 labeled acne cases and reached an R-squared of 0.947 on a held-out test set of 10,348 cases. The company also reported that licensed clinicians agreed with the AI’s treatment recommendation in about 96% of its most recent 1,000 real-world treatments, with disagreements limited to single-step strength adjustments within the same medication class. Dr. Zaid Fadul, the overseeing physician, said the system selects from pre-approved, physician-reviewed protocols rather than making freeform decisions, with clinicians built into every stage.

Access-Gap Figures and Earlier Utah Pilots

Nolla’s state proposal cites Utah dermatology wait times averaging about 61 days against a 32.3-day national median, eleven counties with no dermatologist, an estimated 100,000 Utahns with active acne at any given time of whom about 10% ever reach one, and in-person visit costs of $150 to $300. The Nolla app launched in the United States in summer 2025 and, according to the company, has been downloaded by more than 175,000 people across 44 states; the proposal discloses seed financing from General Catalyst.

Utah’s previous prescribing pilots authorized renewals rather than new prescriptions. The state’s record shows the Doctronic pilot, active since October 24, 2025, processes renewals of existing prescriptions and remains in its first phase, in which a licensed practitioner authorizes every request. The office signed two further pilot agreements on October 2, 2026, with Expect Fitness for pelvic floor physical therapy and August AI for routine refills, and it holds master agreements with University of Utah Health and Intermountain Health. Under the Nolla agreement, monthly reports to the office are due by the 15th of the following month, and a final report is due no later than 30 days before the demonstration period expires.